Re: Sarcopenia is a Poor Prognostic Factor of Castration-Resistant Prostate Cancer Treated with Docetaxel Therapy

被引：0
|
作者：
Griebling, Tomas L.
机构：
来源：
JOURNAL OF UROLOGY | 2020年 / 203卷 / 01期
关键词：
D O I：
10.1097/01.JU.0000604840.21681.4b
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：10 / 11
页数：2
相关论文
共 50 条
  • [1] Sarcopenia is a poor prognostic factor of castration-resistant prostate cancer treated with docetaxel therapy
    Ohtaka, Ayako
    Aoki, Hiroaki
    Nagata, Masayoshi
    Kanayama, Mayuko
    Shimizu, Fumitaka
    Ide, Hisamitsu
    Tsujimura, Akira
    Horie, Shigeo
    PROSTATE INTERNATIONAL, 2019, 7 (01) : 9 - 14
  • [2] The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel
    Bourdoumis, Andreas
    Chrisofos, Michael
    Stasinou, Theodora
    Christopoulos, Panagiotis
    Mourmouris, Panagiotis
    Kostakopoulos, Athanasios
    Deliveliotis, Charalambos
    ANTICANCER RESEARCH, 2015, 35 (05) : 3075 - 3079
  • [3] Glasgow Prognostic Score As a Prognostic Factor in Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel-Based Chemotherapy
    Linton, Anthony
    Pond, Greg
    Clarke, Stephen
    Vardy, Janette
    Galsky, Matthew
    Sonpavde, Guru
    CLINICAL GENITOURINARY CANCER, 2013, 11 (04) : 423 - 430
  • [4] Inflammatory factor-based prognostic risk stratification for patients with metastatic castration-resistant prostate cancer treated with docetaxel
    Shi, Xinyu
    Fan, Junjie
    Pei, Xinqi
    Wang, Yuzhao
    Guo, Guodong
    Yang, Tao
    Wang, Xinyang
    He, Dalin
    Li, Lei
    ANDROLOGIA, 2021, 53 (06)
  • [5] Docetaxel-based combination therapy for castration-resistant prostate cancer
    Galsky, M. D.
    Vogelzang, N. J.
    ANNALS OF ONCOLOGY, 2010, 21 (11) : 2135 - 2144
  • [6] CLINICAL EFFICACY, FEASIBILITY, AND PROGNOSTIC FACTORS FOR SEQUENTIAL DOCETAXEL THERAPY IN THE PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER
    Tanaka, Hajime
    Yuasa, Takeshi
    Ito, Masaya
    Saito, Kazutaka
    Sakura, Mizuaki
    Kitsukawa, Shinichi
    Urakami, Shinji
    Yamamoto, Shinya
    Masuda, Hitoshi
    Fukui, Iwao
    Yonese, Junji
    JOURNAL OF UROLOGY, 2013, 189 (04): : E392 - E392
  • [7] Higher serum testosterone levels predict poor prognosis in castration-resistant prostate cancer patients treated with docetaxel
    Ando, Keisuke
    Sakamoto, Shinichi
    Takeshita, Nobushige
    Fujimoto, Ayumi
    Maimaiti, Maihulan
    Saito, Shinpei
    Sanjyon, Pae
    Imamura, Yusuke
    Sato, Nobuo
    Komiya, Akira
    Akakura, Koichiro
    Ichikawa, Tomohiko
    PROSTATE, 2020, 80 (03): : 247 - 255
  • [8] Continuing enzalutamide with docetaxel in castration-resistant prostate cancer
    Shiota, Masaki
    LANCET ONCOLOGY, 2022, 23 (11): : 1345 - 1347
  • [9] Dasatinib combined with docetaxel for castration-resistant prostate cancer
    Araujo, John C.
    Mathew, Paul
    Armstrong, Andrew J.
    Braud, Edward L.
    Posadas, Edwin
    Lonberg, Mathew
    Gallick, Gary E.
    Trudel, Geralyn C.
    Paliwal, Prashni
    Agrawal, Shruti
    Logothetis, Christopher J.
    CANCER, 2012, 118 (01) : 63 - 71
  • [10] Is docetaxel-free interval a predictive factor for castration-resistant prostate cancer?
    Ay, S.
    Efiloglu, O.
    Ozyukseler, D. Tataroglu
    Dulgar, O.
    Gunaydin, U. Mutlu
    Yildirim, A.
    Gumus, M.
    ACTAS UROLOGICAS ESPANOLAS, 2022, 46 (09): : 550 - 556
12345